One More Approval for Merck’s Keytruda
June 15, 2018
Source: Fierce Pharma
658
Merck’s blockbuster immune-oncology drug, Keytruda has yet again received approval from the FDA.
On Wednesday, a day after Keytruda got the thumbs up for cervical cancer, the drug was approved for treatment of a rare form of non-Hodgkin lymphoma patients who cancer returned after at least two previous treatment lines. Last year, Keytruda also got an indication for classical Hodgkin lymphoma.
At the moment Keytruda is number one in the lung cancer market, where is dwarfing opposition from Imfinzi from AstraZeneca, Bristol-Myers Squibb’s Opdivo, Roche’s Tecentriq, and KGaA’s Bavencio from Pfizer and Merck.
After studies proved that the drug was able to get a 45% response rate in trail participants for PMBCL, it also got an accelerated green light from the FDA for adult and pediatric patients.
Keytruda did, however, face some setbacks last year when, after various trail deaths, the FDA halted multiple myeloma studies.
By Ddu
Copyright©2024 Ddu. All rights reserved.
Read more on
- CRUK researchers develop new early-stage rectal cancer treatment December 12, 2020
- Study Discovers New Mechanism of Immune System to Fight Disease September 3, 2018
- Merck’s New Digital Diabetes Coaching to Educate and Manage Patients August 31, 2018
- Researchers Move Forward In Their Search for Non-Addictive Analgesic August 31, 2018
- J&J Prepares for Appeal after Judge’s Multibillion-Dollar Verdict Against its Talc Defence August 27, 2018
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
